AndroGel Compounded vs Branded: A Clinical Comparison

What Is AndroGel and Who Needs It?

AndroGel is a hydroalcoholic testosterone gel applied to the skin once daily to treat male hypogonadism, a condition defined by the Endocrine Society as a serum total testosterone below 300 ng/dL on two morning measurements combined with consistent symptoms. The gel delivers testosterone transdermally, bypassing first-pass hepatic metabolism and avoiding the peaks and troughs associated with injectable cypionate or enanthate.

Hypogonadism Prevalence and Diagnostic Criteria

The condition is more common than most clinicians expect. Data from the CDC's National Health and Nutrition Examination Survey indicate that approximately 2.1 to 5.7% of men aged 30 to 79 meet biochemical criteria for hypogonadism, with prevalence rising steeply after age 60 (CDC NHANES data). Symptoms include reduced libido, fatigue, decreased muscle mass, and depressed mood. The Endocrine Society's 2018 Clinical Practice Guideline specifies that testosterone therapy is appropriate only when both biochemical and symptomatic criteria are met (Endocrine Society guideline).

How Topical Delivery Works

After application to clean, dry skin on the shoulders, upper arms, or abdomen, testosterone diffuses through the stratum corneum into dermal capillaries. Absorption efficiency averages 10% of the applied dose for AndroGel 1%, producing a relatively flat serum concentration profile compared with intramuscular injections. Peak serum levels typically occur 2 to 4 hours post-application and remain within the eugonadal range (300 to 1,000 ng/dL) throughout the dosing interval when the product is used correctly (FDA label, AndroGel 1%).

Branded AndroGel: Formulations, Dosing, and Pharmacokinetics

AbbVie markets two concentrations of AndroGel in the United States. Understanding the differences between them matters when transitioning a patient or evaluating a compounded alternative.

AndroGel 1% vs AndroGel 1.62%

AndroGel 1% is available in unit-dose packets (25 mg and 50 mg testosterone) and delivers a starting dose of 50 mg testosterone daily. AndroGel 1.62% comes as a metered-dose pump, with each actuation delivering 20.25 mg testosterone. The starting dose is typically 40.5 mg (two pump actuations) applied to the upper arms or shoulders. The 1.62% formulation achieves comparable serum testosterone levels at a lower applied volume, which may reduce transfer risk slightly by limiting the total surface area covered (FDA label, AndroGel 1.62%).

Key Pharmacokinetic Data

The original AndroGel 1% NDA included pharmacokinetic studies showing that 50 mg/day raised mean serum total testosterone from a baseline of approximately 235 ng/dL to 492 ng/dL at day 30, with 77% of subjects achieving levels within the normal range (300 to 1,000 ng/dL). Increasing the dose to 100 mg/day raised mean serum T to 843 ng/dL. These data formed the basis for the FDA's approval in 2000 (FDA label, AndroGel 1%).

The T-Trials: What the Largest Topical Testosterone Study Found

The Testosterone Trials (T-Trials) represent the most comprehensive evaluation of testosterone therapy in older men with low testosterone to date. Published in the New England Journal of Medicine in 2016, the T-Trials enrolled 790 men aged 65 or older with a serum testosterone below 275 ng/dL and randomized them to testosterone gel or placebo gel for 12 months (Snyder et al., NEJM 2016).

Key Efficacy Findings

Testosterone-treated men achieved mean serum total testosterone of approximately 500 ng/dL, compared with 230 ng/dL in the placebo arm. Sexual function scores improved significantly: the sexual activity domain of the Psychosexual Daily Questionnaire increased by 1.3 points versus 0.3 points for placebo (P<0.001). Walking distance in the 6-minute walk test improved modestly but did not reach statistical significance. Bone mineral density at the lumbar spine increased by 3.5% in the testosterone group versus 1.0% in the placebo group (Snyder et al., NEJM 2016).

Cardiovascular Signal and Why It Matters

The T-Trials found a higher rate of coronary artery noncalcified plaque volume in testosterone-treated men: progression of 41 mm³ versus 27 mm³ in the placebo group (P<0.001). The FDA subsequently required label updates for all approved testosterone products. This signal applies equally to compounded testosterone gel because the biological effect is testosterone-mediated, not formulation-specific (Budoff et al., JAMA 2017).

Compounded Testosterone Gel: How It Differs

A 503A compounding pharmacy prepares testosterone gel for an individual patient based on a valid prescription. The gel typically uses testosterone powder suspended in a hydroalcoholic or lipoderm base, at concentrations ranging from 1% to 10% depending on the prescriber's instructions.

Regulatory Framework for 503A Pharmacies

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are exempt from FDA's new drug approval requirements when preparing individualized prescriptions. However, they remain subject to state pharmacy board oversight and must use USP-grade active pharmaceutical ingredients. The FDA does not conduct the same premarket potency, sterility, or bioavailability testing for compounded preparations that it requires for branded drugs (FDA, 503A compounding).

Potency and Bioavailability Variability

A 2017 study published in JAMA Internal Medicine analyzed 29 compounded testosterone products from 12 pharmacies and found that actual testosterone content ranged from 69% to 124% of the labeled dose, with 25% of samples falling outside the USP's acceptable 90 to 110% range (Mullen et al., JAMA Internal Medicine). This variability has direct clinical implications: a patient expecting 50 mg of testosterone may receive anywhere from 34.5 mg to 62 mg, making it harder to titrate to a target serum level.

Cost Advantage

The cost difference is real and substantial. A 30-day supply of branded AndroGel 1.62% retails for $450, $600 without insurance, while a comparable compounded testosterone 1.62% gel from a licensed 503A pharmacy typically costs $40, $120. For patients without prescription drug coverage or with high-deductible plans, this gap drives most formulary decisions (GoodRx data, accessed 2025).

Head-to-Head Comparison: Branded vs Compounded

The table below summarizes the clinically relevant differences.

| Feature | AndroGel (Branded) | Compounded Testosterone Gel | |---|---|---| | FDA approval | Yes | No (503A exemption) | | Potency verified | Yes (NDA lot-release testing) | Variable (pharmacy-dependent) | | Available concentrations | 1%, 1.62% | 1%, 10% (custom) | | Cost without insurance | $400, $600/month | $40, $120/month | | Insurance coverage | Usually covered (prior auth common) | Rarely covered | | Transfer risk labeling | Black-box warning | Same risk, no mandatory label | | Dose flexibility | Limited to packet/pump sizes | High (any dose in milligrams) | | Monitoring requirement | Same | Same |

Secondary Transfer Risk: Equal Concern for Both Formulations

Skin-to-skin transfer of testosterone from treated men to women and children is a class-wide safety concern, not a branded-vs-compounded distinction. The FDA issued a black-box warning for all topical testosterone products in 2009 after reports of virilization in children who had contact with treated skin (FDA Safety Communication 2009).

Minimizing Transfer Risk

Patients should apply gel to the upper arms or shoulders (not the abdomen when children are present), allow 5 to 10 minutes for drying, cover the site with clothing, and wash hands immediately with soap and water. Showering before anticipated skin contact eliminates residual surface testosterone. These steps apply regardless of whether the gel is branded or compounded.

Pharmacokinetic Monitoring: Getting the Dose Right

Both formulations require the same monitoring schedule. Serum total testosterone should be measured 14 days after initiation or any dose change, collected 2 to 8 hours after morning application to capture the approximate Cmax. The Endocrine Society guideline targets a mid-normal serum total testosterone of 400 to 700 ng/dL. If levels fall below 300 ng/dL or exceed 1,050 ng/dL, dose adjustment is required (Endocrine Society guideline).

Hematocrit and Polycythemia Monitoring

Testosterone stimulates erythropoiesis. Hematocrit should be checked at baseline, at 3 months, and then annually. A hematocrit above 54% warrants dose reduction or temporary discontinuation. This risk applies regardless of formulation and is driven by the testosterone molecule, not the delivery vehicle (Endocrine Society guideline).

PSA Monitoring

Prostate-specific antigen should be measured at baseline and at 3 to 6 months. The Endocrine Society recommends referring for urological evaluation if PSA rises more than 1.4 ng/mL above baseline within the first 12 months of therapy, or if a confirmed PSA velocity exceeds 0.4 ng/mL per year (Endocrine Society guideline).

When Compounded Testosterone Gel Makes Clinical Sense

Compounded gels are appropriate in specific, well-defined circumstances.

Dose Requirements Outside Branded Ranges

A patient requiring 30 mg/day of testosterone cannot achieve that dose with AndroGel 1.62% pump actuations (which deliver 20.25 mg or 40.5 mg) or AndroGel 1% packets (25 mg or 50 mg). A compounded 1% or 1.62% gel can be formulated to deliver any milligram dose. Clinicians managing patients with intermediate dose requirements, or those titrating slowly to minimize erythrocytosis risk, find this flexibility clinically valuable.

Higher-Concentration Gels for Better Adherence

Some patients dislike applying large volumes of gel, particularly in warm climates. A compounded 5% or 10% testosterone gel delivers the same absolute testosterone dose in one-third to one-fifth the volume. No FDA-approved product currently offers concentrations above 1.62%, making compounding the only route to higher-concentration topical testosterone in the United States.

Insurance Denials and Cost Barriers

When a patient with confirmed hypogonadism faces a $500/month out-of-pocket cost for branded AndroGel, the clinical risk of non-adherence likely exceeds the regulatory and potency risks of a well-vetted 503A pharmacy. Selecting a compounding pharmacy that uses USP-verified testosterone powder, publishes Certificate of Analysis results, and undergoes voluntary PCAB (Pharmacy Compounding Accreditation Board) accreditation mitigates potency variability.

When Branded AndroGel Is the Better Choice

Several clinical situations favor the branded product specifically.

Patients Where Dose Precision Is Critical

Men with borderline hematocrit (50 to 53%) or those with a history of polycythemia need precise, reproducible dosing. A small undetected potency variation in a compounded product could push hematocrit from 53% to 55% within 60 days. Branded lots must meet USP 90 to 110% potency specifications and are released only after lot testing.

Medicolegal and Insurance Documentation

Branded prescriptions create a clear, auditable medication record. Some disability, life insurance, and workers' compensation evaluations require FDA-approved drug documentation. Compounded prescriptions may not meet those documentation standards in all jurisdictions.

Pediatric Exposure Households

While transfer risk exists for both formulations, branded products carry mandated patient guides and standardized labeling that clearly outline protective steps. Compounded products have no federally required labeling, and the quality of patient counseling varies by pharmacy.

Choosing a Compounding Pharmacy: Quality Markers to Demand

Not all 503A pharmacies operate at the same quality level. Prescribers and patients should verify:

• PCAB accreditation (Pharmacy Compounding Accreditation Board)
• Published Certificate of Analysis for each batch, showing testosterone content within 95 to 105% of label
• Use of USP-monograph testosterone powder from a registered API supplier
• Documented beyond-use dating validated by stability testing, not simply assumed

A 2021 FDA inspection report found that 18 of 31 compounding pharmacies inspected had at least one significant deviation from good compounding practices (FDA Compounding Quality 2021 report). Pharmacy selection is a clinical decision, not just a convenience decision.

The Regulatory Outlook: What May Change

The FDA's ongoing review of testosterone under the Endocrine Disruptors program and the broader 2023 discussions around 503B outsourcing facilities may affect access to compounded testosterone in coming years. Testosterone is not currently on the FDA's 503B bulk substances list for outsourcing facilities, meaning large-scale compounding for office-use supply is restricted. Individual 503A prescriptions remain legal but require a patient-specific order (FDA 503B bulk drug substances list).

The Endocrine Society's position, stated in its 2018 guideline, is that "we suggest using FDA-approved formulations when available and affordable." This reflects a preference, not a prohibition, and leaves room for compounding when clinical circumstances justify it (Endocrine Society guideline).

Practical Prescribing Decision Framework

The decision between branded AndroGel and compounded testosterone gel reduces to four variables:

1. Dose requirement. If the needed dose falls outside 25 mg, 40.5 mg, 50 mg, 81 mg, or 100 mg, compounding is the practical route.
2. Insurance coverage. Prior authorization for AndroGel succeeds in roughly 60 to 70% of first submissions with documented low morning testosterone and symptoms. If denied, compounding is cost-appropriate.
3. Pharmacy quality. Compounding is acceptable only from a PCAB-accredited pharmacy with published Certificates of Analysis.
4. Patient risk profile. Patients with borderline hematocrit, a history of polycythemia, or children in close-contact households benefit most from the potency precision of a branded product.

Monitoring protocol does not change based on formulation. Total testosterone at 14 days post-initiation, hematocrit and PSA at 3 months, and annual labs thereafter apply regardless of whether the tube says "AndroGel" or comes from a compounding pharmacy.